The NCYT share price exploded by 6,450% in 2020. Can it do it again?

The NCYT share price was one of the highest performing stocks in 2020, rising by more than 64 times! Is it too late to invest? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Novacyt (LSE:NCYT) share price exploded by 6,450% in 2020, increasing from 13p to 852p in a single year! The share price has since fallen to 685p since, but that’s still a massive 5,270% surge. What caused this outstanding level of growth? Can it happen again? And should I be adding the stock to my portfolio?

The soaring NCYT share price

NCYT is a medical diagnostics company that develops and sells a range of pathogen testing kits. These are typically used within the medical, life science, and food industries. Before 2020 these products provided a steady stream of reliable and slowly increasing revenue.

But then the pandemic hit, creating the biggest opportunity for NCYT since its inception in 2006. To help fight Covid-19, the company launched the first rapid testing kit in January last year. This was the spark that led to NCYT’s share price explosion. 

By September, the share price has already increased to 380p surrounding speculation on sales performance. And then it released its half-year results for 2020, which CEO Graham Mullis called “transformational”. He wasn’t exaggerating.

Due to the massive demand and limited supply of rapid Covid-19 tests, NCYT received a monumental amount of orders that led to a 900% growth in sales. Total revenue increased to €72.4m from €7.2m a year before. And underlying profits rose from a loss of €0.66m to a gain of €48.3m.

Needless to say, when a company can boost revenue by nine times, become profitable, and solidifies its balance sheet in the space of six months, an explosion in its share price is perfectly understandable.

Can it continue to grow?

Even after NCYT’s surge in share price, the company continues to trade at a P/E ratio of around 14. That is pretty low compared to some of the other diagnostic companies out there. So it certainly seems to have the capacity to grow further.

However, I doubt another 6,450% explosion will be happening anytime soon. There is no denying that the revenue boost is outstanding. But it originated almost entirely from the sale of rapid Covid-19 tests at a time when there weren’t many alternatives.

Today there are considerably more companies providing their own versions of these tests. So NCYT no longer has a monopoly on this market space. I believe demand will continue to rise in 2021 and possibly even 2022. And thus, the firm will continue to benefit from these sales. But over the long term, I think its success will ultimately be determined by how it invests its newly found wealth.

The NCYT share price has its risks

The bottom line

Without knowing how the firm intends to sustain its current level of revenue generation, I think it’s tricky to determine whether NCYT is a good investment even at its seemingly low share price. Personally, I’m waiting for more information, as there are simply too many unknowns about its longevity.

But suppose the management team can identify new ways to expand sales of its existing products unrelated to Covid-19. In that case, I may have to reconsider adding the stock to my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Novacyt. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »